Home » Newsletters » BioWorld

BioWorld

Oct. 4, 1995

View Archived Issues

MICROPROBE SELLS DIAGNOSTICS BUSINESS TO BECTON DICKINSON

OTHER NEWS TO NOTE

ABRUPTLY CLOUDED VISION CLUES IN CLINICIANS TO UNSUSPECTED LUNG TUMOR

GILEAD SCIENCES SUBMITS NEW DRUG APPLICATION FOR VISTIDE

SYNCOR TO DISTRIBUTE NEOPROBE'S RIGS PRODUCTS

BIOMIRA'S TRUQUANT RECOMMENDED FOR APPROVAL

SANDOZ TAPS PHARMACOPEIA'S COMBINATORIAL CHEMISTRY FOR DRUG DISCOVERY

BIOMARKER IDENTIFIED FOR CELL AGING IN VIVO

SCIOS NOVA RE-FOCUSES CLINICAL TRIALS OF AURICULIN TO OLIGURIC ACUTE

NORTH AMERICAN VACCINE SIGNS $50M PACT WITH PASTEUR MERIEUX

BIOTECHNOLOGY STOCKS TAKE A BATH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...